BR112015030589A2 - formas polimórficas de fosfato de icotinibe e seus usos - Google Patents

formas polimórficas de fosfato de icotinibe e seus usos

Info

Publication number
BR112015030589A2
BR112015030589A2 BR112015030589A BR112015030589A BR112015030589A2 BR 112015030589 A2 BR112015030589 A2 BR 112015030589A2 BR 112015030589 A BR112015030589 A BR 112015030589A BR 112015030589 A BR112015030589 A BR 112015030589A BR 112015030589 A2 BR112015030589 A2 BR 112015030589A2
Authority
BR
Brazil
Prior art keywords
polymorphic forms
icotinib phosphate
icotinib
phosphate
forms
Prior art date
Application number
BR112015030589A
Other languages
English (en)
Other versions
BR112015030589B1 (pt
BR112015030589A8 (pt
Inventor
Wang Fei
Ding Lieming
Hu Shaojing
Long Wei
Wang Yinxiang
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of BR112015030589A2 publication Critical patent/BR112015030589A2/pt
Publication of BR112015030589A8 publication Critical patent/BR112015030589A8/pt
Publication of BR112015030589B1 publication Critical patent/BR112015030589B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/14—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Piezo-Electric Or Mechanical Vibrators, Or Delay Or Filter Circuits (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

resumo patente de invenção: "formas polimórficas de fosfato de icotinibe e seus usos". a presente invenção refere-se a fosfato de icotinibe (isto é, o composto de fórmula (i)) e suas formas polimorfas, e processos de preparação e uso das mesmas.
BR112015030589-0A 2013-06-09 2014-06-09 Formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas BR112015030589B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013077091 2013-06-09
CNPCT/CN2013/077091 2013-06-09
PCT/CN2014/079488 WO2014198211A1 (en) 2013-06-09 2014-06-09 New polymorphic forms of icotinib phosphate and uses thereof

Publications (3)

Publication Number Publication Date
BR112015030589A2 true BR112015030589A2 (pt) 2017-07-25
BR112015030589A8 BR112015030589A8 (pt) 2020-01-07
BR112015030589B1 BR112015030589B1 (pt) 2022-07-05

Family

ID=52021657

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030589-0A BR112015030589B1 (pt) 2013-06-09 2014-06-09 Formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas

Country Status (13)

Country Link
US (1) US9688687B2 (pt)
EP (1) EP3007700B1 (pt)
JP (1) JP6523259B2 (pt)
KR (1) KR102270538B1 (pt)
AU (1) AU2014280710B2 (pt)
BR (1) BR112015030589B1 (pt)
CA (1) CA2914698C (pt)
ES (1) ES2638646T3 (pt)
HK (1) HK1207589A1 (pt)
RU (1) RU2712169C2 (pt)
SG (1) SG11201509753SA (pt)
TW (1) TWI535724B (pt)
WO (1) WO2014198211A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014280710B2 (en) * 2013-06-09 2016-12-22 Betta Pharmaceuticals Co., Ltd New polymorphic forms of Icotinib phosphate and uses thereof
EP4034137A4 (en) * 2019-09-27 2023-09-20 Duke University COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF PANCREATITIS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
US7078409B2 (en) * 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
NZ590334A (en) * 2008-07-08 2012-12-21 Beta Pharma Inc ICOTINIB HYDROCHLORIDE (4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crownquinazoline hydrochloride), SYNTHESIS, CRYSTALLOGRAPHIC FORM, MEDICAL COMBINATION, AND USES THEREOF
SG11201401953WA (en) 2011-10-31 2014-09-26 Betta Pharmaceuticals Co Ltd Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof
AU2014280710B2 (en) 2013-06-09 2016-12-22 Betta Pharmaceuticals Co., Ltd New polymorphic forms of Icotinib phosphate and uses thereof
JP6216869B2 (ja) 2013-06-09 2017-10-18 ベータ ファーマシューティカルズ カンパニー リミテッド イコチニブの多形及びその使用
RU2698796C2 (ru) 2013-10-11 2019-08-30 Бетта Фармасьютикалз Ко., Лтд Икотиниб-содержащие местнодействующие накожные фармацевтические композиции и их применения

Also Published As

Publication number Publication date
KR20160018714A (ko) 2016-02-17
TWI535724B (zh) 2016-06-01
US20160145262A1 (en) 2016-05-26
JP6523259B2 (ja) 2019-05-29
ES2638646T3 (es) 2017-10-23
TW201512204A (zh) 2015-04-01
BR112015030589B1 (pt) 2022-07-05
RU2712169C2 (ru) 2020-01-24
EP3007700B1 (en) 2017-06-28
HK1207589A1 (zh) 2016-02-05
CA2914698A1 (en) 2014-12-18
RU2016100027A (ru) 2017-07-18
AU2014280710B2 (en) 2016-12-22
CA2914698C (en) 2017-08-22
KR102270538B1 (ko) 2021-06-29
AU2014280710A1 (en) 2016-01-21
US9688687B2 (en) 2017-06-27
EP3007700A4 (en) 2016-08-10
JP2016520625A (ja) 2016-07-14
EP3007700A1 (en) 2016-04-20
SG11201509753SA (en) 2015-12-30
BR112015030589A8 (pt) 2020-01-07
WO2014198211A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
EA201692219A1 (ru) Способы получения противовирусных соединений
CU24603B1 (es) Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
BR112014030365A2 (pt) síntese de composto antiviral
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CR20140435A (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
BR112016027691A2 (pt) Composto de tetra-hidropiridopirimidina e seus usos
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
JOP20200030A1 (ar) مركب خماسي الحلقة
ECSP13012366A (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
BR112018006005A2 (pt) composto bicíclico e uso do mesmo para inibição de suv39h2
WO2014172363A3 (en) Combretastatin analogs
CR20140531A (es) Derivados de ariletinilo
WO2015062937A3 (en) Disperse dyes, their preparation and their use
BR112015030589A2 (pt) formas polimórficas de fosfato de icotinibe e seus usos
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
CR20150028A (es) Derivados de ariletinilo
CU20150015A7 (es) Tris-(hetero)aril-pirazoles y su uso
BR112015020611A2 (pt) compostos de carboxamida
EA201690593A1 (ru) Новые соединения мочевины
EA201690908A1 (ru) Пиразолопиримидиновые соединения

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/06/2014, OBSERVADAS AS CONDICOES LEGAIS